Korian: H1 2016 Revenue of €1,470.4 Million (+16.3%)
A solid organic growth of 4%
Sales target for 2016 confirmed
Korian’s revenue of €1470.4 million at
REPORTED HALF-YEAR REVENUE (1)
| In €m (unaudited IFRS figures) | 1st half | Growth | ||||||
| 2016 | 2015 | Reported | Organic (2) | |||||
| |
778.1 | 757.9 | 2.7% | 2.3% | ||||
| in % of rev. | 52.9% | 60.0% | ||||||
| International | 692.3 | 506.1 | 36.8% | 6.6% | ||||
| in % of rev. | 47.1% | 40.0% | ||||||
| |
419.5 | 246.9 | 69.9% | 9.2% | ||||
| |
156.2 | 153.2 | 2.0% | 2.6% | ||||
| |
116.6 | 106.0 | 10.1% | 6.4% | ||||
| |
1,470.4 | 1,264.0 | 16.3% | 4.0% | ||||
Robust business in
Revenue in
The revenue of the Healthcare division (post-acute and rehabilitation care clinics) also grew, thanks to occupancy rates of 98% and sales of additional services, which offset some of the decrease in health insurance rates observed in the 1st half of the year. The period saw 13% revenue growth of Korian France’s restructured facilities, which represent a total of 367 beds, in addition to the 241 beds acquired in H1 2016.
International subsidiaries post 6.6% organic growth
Korian’s international subsidiaries generated 1st half revenue of €692.3 million, which accounts for over 47% of total Group revenue. The 36.8% revenue growth in H1 is attributable to robust organic growth of 6.6%, the acquisitions made in 2015 in each country where the Group is present, and the consolidation of
Revenue growth in
In
Revenue in
Dividend distribution
On 22 July,
Korian’s share capital now amounts to €400,890,210 and is divided in 80,178,042 shares.
A total cash dividend of €28.6 million will be paid to shareholders on 22 July.
Next event:
H1 2016 results
(1) Revenue and other income
(2) Organic revenue growth includes: a) the change in the revenue between year Y and year
2ND QUARTER REVENUE (1)
| In €m (unaudited IFRS figures) | 2nd quarter | Growth | ||||||
| 2016 | 2015 | Reported | Organic (2) | |||||
| |
390.7 | 380.0 | 2.8% | 2.5% | ||||
| in % of rev. | 52.8% | 59.8% | ||||||
| International | 349.3 | 255.9 | 36.5% | 6.1% | ||||
| in % of rev. | 47.2% | 40.2% | ||||||
| |
211.4 | 124.6 | 69.6% | 8.7% | ||||
| |
78.9 | 77.2 | 2.3% | 2.3% | ||||
| |
59.0 | 54.0 | 9.1% | 5.4% | ||||
| |
740.0 | 635.9 | 16.4% | 4.0% | ||||
ABOUT
For more information, please visit the website: www.korian.com
Euronext ticker: KORI - ISIN: FR0010386334 – Reuters: KORI.PA – Bloomberg: KORI.FP
View source version on businesswire.com: http://www.businesswire.com/news/home/20160720005980/en/
INVESTOR CONTACT
Investor Relations Director
[email protected]
Tel: +33 (0)1 55 37 53 55
or
PRESS CONTACT
DGM Conseil
[email protected] / [email protected]
T : +33 (0)1 40 70 95 93
Source:


A.M. Best Webinar to Examine the State of the Captive Insurance Market
Advisor News
- Global economic growth will moderate as the labor force shrinks
- Estate planning during the great wealth transfer
- Main Street families need trusted financial guidance to navigate the new Trump Accounts
- Are the holidays a good time to have a long-term care conversation?
- Gen X unsure whether they can catch up with retirement saving
More Advisor NewsAnnuity News
- Prudential launches FlexGuard 2.0 RILA
- Lincoln Financial Introduces First Capital Group ETF Strategy for Fixed Indexed Annuities
- Iowa defends Athene pension risk transfer deal in Lockheed Martin lawsuit
- Pension buy-in sales up, PRT sales down in mixed Q3, LIMRA reports
- Life insurance and annuities: Reassuring ‘tired’ clients in 2026
More Annuity NewsHealth/Employee Benefits News
Life Insurance News
- Best’s Market Segment Report: AM Best Maintains Stable Outlook on Malaysia’s Non-Life Insurance Segment
- Report Summarizes Kinase Inhibitors Study Findings from Saga University Hospital (Simulation of Perioperative Ibrutinib Withdrawal Using a Population Pharmacokinetic Model and Sparse Clinical Concentration Data): Drugs and Therapies – Kinase Inhibitors
- Flawed Social Security death data puts life insurance benefits at risk
- EIOPA FLAGS FINANCIAL STABILITY RISKS RELATED TO PRIVATE CREDIT, A WEAKENING DOLLAR AND GLOBAL INTERCONNECTEDNESS
- Envela partnership expands agent toolkit with health screenings
More Life Insurance News